Targeting of interleukin-17 in the treatment of psoriasis

Clinical, Cosmetic and Investigational Dermatology

Volumn 7, Issue , 2014, Pages 251-259

  Lønnberg, Ann Sophie ^a   Zachariae, Claus ^a   Skov, Lone ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anti IL 17 agents; Brodalumab; IL 17; Ixekizumab; Psoriasis; Secukinumab

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BRODALUMAB; CREATINE KINASE; ETANERCEPT; INTERLEUKIN 17 RECEPTOR; IXEKIZUMAB; PLACEBO; SECUKINUMAB; USTEKINUMAB;

AORTA ANEURYSM; APPENDICITIS; ARM PAIN; ARTHRALGIA; BACTERIAL PNEUMONIA; CANDIDA ALBICANS; CITROBACTER RODENTIUM; COLON CANCER; CYTOKINE PRODUCTION; DERMATOLOGY LIFE QUALITY INDEX; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR INFECTION; ERYTHRODERMIC PSORIASIS; ESOPHAGEAL ADENOCARCINOMA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; INJECTION SITE ERYTHEMA; KLEBSIELLA PNEUMONIAE; LEG PAIN; NAUSEA; NONHUMAN; OPEN STUDY; PATHOGENESIS; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS AREA AND SEVERITY INDEX 75; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUNCH BIOPSY; PUSTULOSIS PALMOPLANTARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; SYSTEMATIC REVIEW; TESTIS CANCER; TH17 CELL; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UTERINE CERVIX CARCINOMA;

EID: 84907876102     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: 10.2147/CCID.S67534     Document Type: Review

References (59)

1. Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health Sys Pharm. 2000;57(7):645-659.
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5): 496-509.
3. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16-17.
4. Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology. 2006;212(4):327-337.
5. Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2012;24 Suppl 2:31-35.
6. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040-1047.
7. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):23-30.
8. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895.
9. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139.
10. Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol. 2007;25(6):547-554.
11. Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. Heritability of psoriasis in a large twin sample. Br J Dermatol. 2013;169(2):412-416.
12. Tsoi LC, Spain SL, Knight J, et al; Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case Control Consortium 2, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341-1348.
13. Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet. 2004;13 Spec No 1: R43-R55.
14. Carpon F, Burden AD, Trembath RC, Barker JN. Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol. 2012;132(3 Pt 2):915-922.
15. Chen H, Poon A, Yeung C, et al. A genetic risk score combining ten psoriasis risk loci improves disease prediction. PLoS One. 2011;6:e19454.
16. Savolainen L, Kontinen J, Alatalo E, Röning J, Oikarinen A. Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis. Acta Derm Venereol. 1998;78(6):466-467.
17. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141(2):185-191.
18. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges. 2007;5(7):566-574. English, German.
19. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23 Suppl 2:1-70.
20. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011;23(5):613-619.
21. Gaffen SL. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556-567.
22. Wright JF, Bennett F, Li B, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008;181(4):2799-2805.
23. Gaffen S, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm. 2006;74:255-282.
24. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717-724.
25. van den Berg WB, McInnes IB. Th17 cells and IL-17 a - focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum. 2013;43:158-170.
26. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22(8):993-1005.
27. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490-500.
28. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature. 2008;453(7198):1051-1057.
29. Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008;454(7202):350-352.
30. Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology. 2009;126(2): 177-185.
31. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65-68.
32. Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 2012;14(4):217.
33. Hernández-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe. 2012;11(5):425-435.
34. Gordon K, Leonardi C, Braun D, et al. Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2014;70(5 Supplement 1):AB183.
35. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763-776.
36. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87-113.
37. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013; 72 Suppl 2:2116-2123.
38. Monteleone G, Pallone F, MacDonald TT, Chimenti S, Costanzo A. Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci (Lond). 2011;120(1):1-11.
39. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9(10):679-691.
40. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17-26.
41. Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9):2175-2183.
42. Gan EY, Chong WS, Tey HL. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. BioDrugs. 2013;27(4):359-373.
43. Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology. 2011;134(1):8-16.
44. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13); 1181-1189.
45. Papp K, Milmont C, Leonardi C, Ortonne JP, Klekotla P. Maintenance of clinical response with long-term brodalumab (AMG 827) therapy for psoriasis: Week 96 results from an open-label extension study. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB174.
46. Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466-2469.
47. Hueber W, Patel DD, Dryja T, et al. Psoriasis Study Group, et al; Rheumatoid Arthritis Study Group, et al; Uveitis Study Group, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52-72.
48. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-421.
49. Sigurgeirsson B, Kircik L, Nemoto O, et al. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. J Eur Acad Dermatol Venereol. Epub December 13, 2013.
50. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2012;168(2):402-411.
51. Paul C, Reich K, Gottlieb AB, et al; The CAIN457A2211 study group. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. Epub January 7, 2014.
52. Reich K, Puig L, Draelos Z, Notter M, Papavassilis C. Sustainability of response with secukinumab to 52 weeks in moderate-to-severe plaque psoriasis: data from the full year investigative examination of secukinumab vs etanercept using 2 dosing regimens to determine efficacy in psoriasis (FIXTURE) study. Abstract/Program number 8101. Presented at the American Academy of Dermatology, March 21-25, 2014, Denver, CO, USA.
53. Warren R, Guettner A, Morita A, Gisondi P, Cooper S. Secukinumab efficacy in subjects with moderate to severe plaque psoriasis: Pooled subgroup analyses by patient age of 4 phase 3 clinical studies. J Am Acad Dermatol. 2014;70(5 Supplement 1):AB186.
54. Elewski B, McLeod L, Lebwohl M, Mallya UG, Zhao Y. Secukinumab versus placebo or etanercept on time to response on patient-reported psoriasis symptoms of pain, itching, and scaling (FIXTURE study). J Am Acad Dermatol. 2014;70(5 Supplement 1):AB189.
55. Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-154.
56. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-1199.
57. Zhu B, Edson-Heredia E, Cameron GS, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013;169(6):1337-1341.
58. Griffiths CE, Prinz J, Güttner A, Cooper S. Behavior of neutrophil count during 52 weeks of treatment with secukinumab: an analysis of pooled data from the phase 2 and phase 3 clinical study programs for secukinumab in moderate-to-severe plaque psoriasis. Abstract/Program number 8266. Presented at the 72nd Annual Meeting of the American Academy of Dermatology, March 21-25, 2014, Denver, CO, USA.
59. Papp K, Nakagawa H, Melendez E, Karpov A, Papavassilis C; ERASURE Study Group. Efficacy in relationship with response to previous biologic psoriasis therapy: a subanalysis from the ERASURE phase 3 study in psoriasis. Abstract/Program number 8011. Presented at the American Academy of Dermatology, March 21-25, 2014, Denver, CO, USA.